Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/38897
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | De Backer, Mickael | - |
dc.contributor.author | LEGRAND, Catherine | - |
dc.contributor.author | Peron, Julien | - |
dc.contributor.author | Lambert, Alexandre | - |
dc.contributor.author | BUYSE, Marc | - |
dc.date.accessioned | 2022-11-21T10:19:52Z | - |
dc.date.available | 2022-11-21T10:19:52Z | - |
dc.date.issued | 2022 | - |
dc.date.submitted | 2022-11-18T12:08:43Z | - |
dc.identifier.citation | PHARMACEUTICAL STATISTICS, 22 (2), p. 284-299 | - |
dc.identifier.uri | http://hdl.handle.net/1942/38897 | - |
dc.description.abstract | In randomized clinical trials, methods of pairwise comparisons such as the 'Net Benefit' or the 'win ratio' have recently gained much attention when interests lies in assessing the effect of a treatment as compared to a standard of care. Among other advantages, these methods are usually praised for delivering a treatment measure that can easily handle multiple outcomes of different nature, while keeping a meaningful interpretation for patients and clinicians. For time-to-event outcomes, a recent suggestion emerged in the literature for estimating these treatment measures by providing a natural handling of censored outcomes. However, this estimation procedure may lead to biased estimates when tails of survival functions cannot be reliably estimated using Kaplan-Meier estimators. The problem then extrapolates to the other outcomes incorporated in the pairwise comparison construction. In this work, we suggest to extend the procedure by the consideration of a hybrid survival function estimator that relies on an extreme value tail model through the Generalized Pareto distribution. We provide an estimator of treatment effect measures that notably improves on bias and remains easily apprehended for practical implementation. This is illustrated in an extensive simulation study as well as in an actual trial of a new cancer immunotherapy. | - |
dc.description.sponsorship | This research was partially funded by the regions of Wallonia (BioWin Consortium Agreement No 7979) | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.rights | 2022 John Wiley & Sons Ltd | - |
dc.subject.other | clinical trial | - |
dc.subject.other | generalized pairwise comparisons | - |
dc.subject.other | generalized Pareto distribution | - |
dc.subject.other | Kaplan-Meier | - |
dc.subject.other | multi-criteria analysis | - |
dc.title | On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomes | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 299 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 284 | - |
dc.identifier.volume | 22 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | De Backer, M (corresponding author), UCLouvain, ISBA LIDAM, Voie Roman Pays 20, B-1348 Louvain La Neuve, Belgium. | - |
dc.description.notes | mickael.debacker@uclouvain.be | - |
local.publisher.place | 111 RIVER ST, HOBOKEN 07030-5774, NJ USA | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1002/pst.2271 | - |
dc.identifier.pmid | 36321470 | - |
dc.identifier.isi | 000877748700001 | - |
dc.contributor.orcid | De Backer, Mickael/0000-0003-1669-6391 | - |
local.provider.type | wosris | - |
local.description.affiliation | [De Backer, Mickael; Legrand, Catherine] UCLouvain, ISBA LIDAM, Voie Roman Pays 20, B-1348 Louvain La Neuve, Belgium. | - |
local.description.affiliation | [Peron, Julien] Univ Lyon 1, Equipe Biostat Sante, Lab Biometrie & Biol Evolut, CNRS,UMR 5558, Villeurbanne, France. | - |
local.description.affiliation | [Peron, Julien] Hosp Civils Lyon, Serv Biostat & Bioinformat, Lyon, France. | - |
local.description.affiliation | [Peron, Julien] Hosp Civils Lyon, Oncol Dept, Lyon, France. | - |
local.description.affiliation | [Lambert, Alexandre] Bristol Myers Squibb, Global Biometr & Data Sci, Braine Lalleud, Belgium. | - |
local.description.affiliation | [Buyse, Marc] Int Drug Dev Inst IDDI, Louvain La Neuve, Belgium. | - |
local.description.affiliation | [Buyse, Marc] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat I BioSt, Diepenbeek, Belgium. | - |
local.uhasselt.international | yes | - |
item.accessRights | Restricted Access | - |
item.validation | ecoom 2023 | - |
item.fulltext | With Fulltext | - |
item.contributor | De Backer, Mickael | - |
item.contributor | LEGRAND, Catherine | - |
item.contributor | Peron, Julien | - |
item.contributor | Lambert, Alexandre | - |
item.contributor | BUYSE, Marc | - |
item.fullcitation | De Backer, Mickael; LEGRAND, Catherine; Peron, Julien; Lambert, Alexandre & BUYSE, Marc (2022) On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomes. In: PHARMACEUTICAL STATISTICS, 22 (2), p. 284-299. | - |
crisitem.journal.issn | 1539-1604 | - |
crisitem.journal.eissn | 1539-1612 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomes.pdf Restricted Access | Published version | 1.62 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.